GlassScriptPhysician profile
Stephen S Tseng
NPI 1952311326
$5,984.02
in general payments reported to CMS, 2019-2025
38 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,551 · 2020: $1,878 · 2021: $2,297 · 2022: $258.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,321.79 | 2019-2022 | |
| Pfizer INC. | $533.68 | 2019-2021 | |
| Lilly USA, LLC | $497.41 | 2020-2021 | |
| Abbvie INC. | $410.04 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $395.53 | 2019-2020 | |
| Astellas Pharma US INC | $388.25 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $311.27 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $265.06 | 2019-2022 | |
| Amgen INC. | $239.74 | 2019-2021 | |
| Amarin Pharma, INC. | $223.45 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $197.09 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $152.65 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $116.33 | 2020-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $94.72 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $86.64 | 2020-2021 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $78.81 | 2021 | |
| Hikma Pharmaceuticals USA | $76.25 | 2019-2021 | |
| Abbott Laboratories | $58.26 | 2021 | |
| Esperion Therapeutics, INC. | $57.17 | 2021 | |
| Itamar Medical INC | $55.61 | 2022 | |
| Genentech USA, INC. | $53.23 | 2019 | |
| Glaxosmithkline, LLC. | $52.89 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $41.67 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $35.59 | 2021 | |
| Philips North America LLC | $26.04 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $22.69 | 2022 | |
| Eyevance Pharmaceuticals LLC | $20.96 | 2021 | |
| Biogen, INC. | $19.33 | 2021 | |
| Antares Pharma, INC. | $17.54 | 2021 | |
| Dexcom, INC. | $16.65 | 2021 | |
| Ibsa Pharma INC. | $16.60 | 2020 | |
| Allergan, INC. | $16.44 | 2020 | |
| Eisai INC. | $15.65 | 2021 | |
| Acerus Pharmaceuticals Corporation | $15.28 | 2021 | |
| Medtronic, INC. | $14.54 | 2021 | |
| Seqirus USA INC | $14.44 | 2019 | |
| Medtronic Minimed, INC. | $12.38 | 2020 | |
| Arbor Pharmaceuticals, INC. | $12.35 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Tseng listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.